The specter of a drug-resistant form of the deadly H5N1 avian influenza is a nightmare to keep public health officials awake at night. Now, however, a study published this week (Dec…

Medicago Inc. (TSX-V: MDG) a biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), reported positive interim results from a Phase I human clinical trial with its H5N1 Avian Influenza vaccine candidate (”H5N1 vaccine”)…

Learn more about how gene therapy may help slow down inherited emphysema.